# Domain Associates: portfolio, investments and team

> Domain Associates is a vc firm based in United States. 182 investments on record, latest Dec 2019. Portfolio, stages, co-investors and team.

Source: https://millionrounds.com/fund/domain-associates (Millionrounds; every figure on the page links to its filing or article)

United States · [Investor](https://millionrounds.com/investors)

# Domain Associates

Last cheque observed Dec 2019. Silence since then is not evidence of inactivity: our sources miss unannounced rounds.

Email

Quiet New fund $164M, Dec 2016 VC firm

Seed Series A Series B Tech-enabled Health Connected-health Longevity

Follow Domain Associates and see its new cheques in your feed. [Start following](https://millionrounds.com/login?join=1&why=follow&next=%2Ffund%2Fdomain-associates)

Cheques on record

**0%** of best year **0** **cheques in 12 months**, 182 on record

Since the last cheque **2510** days **00** hrs **00** min **00** sec

Median round **$28M** Rounds led **1 of 182** Sole investor **5 rounds** Exits **24 from the portfolio** Mostly in **United States, 88%**

Pitch Domain Associates

## Domain Associates highlights

- 01 182 rounds on record
- 02 Mostly Series B and Series C: 57% of its rounds
- 03 Sole investor in 5 rounds, median $2.0M
- 04 24 exits from the portfolio

## What they do

> INVESTMENT ADVISORS TO THE FIRST VC FUND DEDICATED TO BIOTECH From their own website

- **Type:** VC firm (from a list, unverified)
- **Cheque size:** Up to $5.0M as they say
- **Stages:** Seed Series A Series B Growth Pre-IPO
- **Sectors:** Tech-enabled Health Connected-health Longevity
- **Based in:** San Diego, United States
- **Cold pitches:** Not accepted

## The record

Every round we can evidence, newest first **182 appearances**

- **2019** 5 rounds
- **Dec** **[ChromaCode](https://millionrounds.com/company/chromacode)** Series C · US · FinSMEs **$28M** With 6 others
- **Dec** **[Aspen Neuroscience](https://millionrounds.com/company/aspen-neuroscience)** Seed · US · FinSMEs **$6.5M** *Led*
- **Nov** **[Truvian Sciences](https://millionrounds.com/company/truvian-sciences)** Series B · US · FinSMEs **$27M** With 3 others
- **Nov** **[Sera Prognostics](https://millionrounds.com/company/sera-prognostics)** Series D · US · FinSMEs **$36M** With 5 others
- **Feb** **[Axial Biotherapeutics](https://millionrounds.com/company/axial-biotherapeutics)** Series B · US · FinSMEs **$25M** With 2 others
- **2018** 1 round
- **Jun** **[WindML](https://millionrounds.com/company/windml)** Series B · US · FinSMEs **$33M** With 3 others
- **2017** 1 round
- **May** **[Iterum Therapeutics](https://millionrounds.com/company/iterum-therapeutics)** Series B · IE · FinSMEs **$65M** With 3 others
- **2016** 1 round
- **Dec** **[Axial Biotherapeutics](https://millionrounds.com/company/axial-biotherapeutics)** Series A · US · FinSMEs **$19M** With 1 other
- **2015** 7 rounds
- **Nov** **[Fractyl Laboratories](https://millionrounds.com/company/fractyl-laboratories)** Series C · US **$57M** With 4 others
- **Aug** **[Syndax Pharmaceuticals](https://millionrounds.com/company/syndax-pharmaceuticals)** Series C · US **$80M** With 12 others
- **Jul** **[Xagenic](https://millionrounds.com/company/xagenic)** Series B · CA **$12M** With 3 others
- **Jun** **[Sebacia](https://millionrounds.com/company/sebacia)** Series C · US **$12M** With 3 others
- **Jun** **[Milestone Pharmaceuticals](https://millionrounds.com/company/milestone-pharmaceuticals)** Series B · CA **$17M** With 5 others
- **Jan** **[CoLucid Pharmaceuticals](https://millionrounds.com/company/colucid-pharmaceuticals)** Series C · US **$37M** With 7 others
- **Jan** **[Sera Prognostics](https://millionrounds.com/company/sera-prognostics)** Series B · US **$20M** With 4 others
- **2014** 13 rounds
- **Nov** **[BioNano Genomics](https://millionrounds.com/company/bionano-genomics)** Series C · US **$53M** With 4 others
- **Nov** **[Sera Prognostics](https://millionrounds.com/company/sera-prognostics)** Series B · US **$5.0M** With 3 others
- **Oct** **[Miramar Labs](https://millionrounds.com/company/miramar-labs)** Series D · US **$26M** With 4 others
- **Sept** **[Zyga Technology](https://millionrounds.com/company/zyga-technology)** Series D · US **$2.0M** With 3 others
- **Sept** **[VentiRx Pharmaceuticals](https://millionrounds.com/company/ventirx-pharmaceuticals)** Series B · US **$51M** With 4 others
- **Sept** **[Fractyl Laboratories](https://millionrounds.com/company/fractyl-laboratories)** Series B · US **$40M** With 3 others
- **Jul** **[Epic Sciences](https://millionrounds.com/company/epic-sciences)** Series C · US **$30M** With 4 others
- **Jul** **[Xagenic](https://millionrounds.com/company/xagenic)** Series B · CA **$26M** With 4 others
- **Jun** **[Benvenue Medical](https://millionrounds.com/company/benvenue-medical)** Series E · US **$40M** With 4 others
- **Apr** **[Otonomy](https://millionrounds.com/company/otonomy)** Series D · US **$49M** With 11 others
- **Apr** **[Sequent Medical](https://millionrounds.com/company/sequent-medical)** Series D · US **$20M** With 3 others
- **Feb** **[Lithera](https://millionrounds.com/company/lithera)** Series C · US **$8.0M** With 2 others
- **Jan** **[Atara Biotherapeutics](https://millionrounds.com/company/atara-biotherapeutics)** Series B · US **$14M** With 6 others
- **2013** 21 rounds
- **Dec** **[Atara Biotherapeutics](https://millionrounds.com/company/atara-biotherapeutics)** Series B · US **$39M** With 5 others
- **Dec** **[Xagenic](https://millionrounds.com/company/xagenic)** Series B · CA · finsmes.com **$20M** With 2 others
- **Nov** **[RightCare Solutions](https://millionrounds.com/company/rightcare-solutions)** Series B · US · finsmes.com **$5.0M** With 1 other
- **Oct** **[NovaDigm Therapeutics](https://millionrounds.com/company/novadigm-therapeutics)** Series B · US · finsmes.com **$14M** With 1 other
- **Oct** **[BioNano Genomics](https://millionrounds.com/company/bionano-genomics)** Series C · US · xconomy.com **$10M** With 2 others
- **Sept** **[Otonomy](https://millionrounds.com/company/otonomy)** Series C · US · finsmes.com **$46M** With 7 others
- **Aug** **[Syndax Pharmaceuticals](https://millionrounds.com/company/syndax-pharmaceuticals)** Series B · US · finsmes.com **$27M** With 3 others
- **Aug** **[Applied Proteomics](https://millionrounds.com/company/applied-proteomics)** Series C · US · finsmes.com **$28M** With 2 others
- **Jul** **[Dicerna Pharmaceuticals](https://millionrounds.com/company/dicerna-pharmaceuticals)** Series C · US · finsmes.com **$60M** With 8 others
- **Jul** **[aTyr Pharma](https://millionrounds.com/company/atyr-pharma)** Series D · US · finsmes.com **$49M** With 3 others
- **Jul** **[ReVision Optics](https://millionrounds.com/company/revision-optics)** Series E · US · finsmes.com **$55M** With 5 others
- **Jun** **[Veracyte](https://millionrounds.com/company/veracyte)** Series C · US · finsmes.com **$28M** With 4 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

## The team

Named by the firm itself, on a filing, its Form ADV or its company registration **8 named**

BH **Brian H. Dovey** Executive Officer i Filing they signed

BK **Brian Keith Halak** Executive Officer i Filing they signed

JC **James Carroll Blair** Executive Officer i Filing they signed

JI **Jesse I. Treu** Executive Officer i Filing they signed

KK **Kathleen K. Schoemaker** Executive Officer i Filing they signed

KP **Kim Puloma Kamdar** Executive Officer i Filing they signed

N(**Nicole (nmn) Vitullo** Managing Member/Chief Compliance Officer i Form ADV

NK **Nimesh K. Shah** Executive Officer i Filing they signed

We also hold **17** people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

## What the register says

From the firm's own filings with the SEC, which it must file accurately by law

**$117M** gross assets of its funds Oct 2026

**Exempt** reporting adviser venture or small private funds

- **Legal name:** Domain Associates, LLC
- **SEC number:** CRD 159846

## Exits from the portfolio

Companies it backed that were later bought or listed **24 in all**

**[Twelve](https://millionrounds.com/company/twelve)** Bought by [Medtronic](https://millionrounds.com/fund/medtronic) **$458M** Aug 2015

**[Meritage Pharma](https://millionrounds.com/company/meritage-pharma)** Bought by [Shire](https://millionrounds.com/fund/shire) **$245M** Feb 2015

**[Ariosa Diagnostics, Inc.](https://millionrounds.com/company/ariosa-diagnostics-inc)** Bought by Roche **$625M** Dec 2014

**[CellBiosciences](https://millionrounds.com/company/cellbiosciences)** Bought by Bio-Techne **Undisclosed** Jun 2014

**[Santarus](https://millionrounds.com/company/santarus)** Bought by [Salix Pharmaceuticals](https://millionrounds.com/fund/salix-pharmaceuticals) **$2.6B** Nov 2013

**[Five Prime Therapeutics](https://millionrounds.com/company/five-prime-therapeutics)** Listed **Undisclosed** Jul 2013

**[Somaxon Pharmaceuticals](https://millionrounds.com/company/somaxon-pharmaceuticals)** Bought by Pernix Therapeutics **Undisclosed** Mar 2013

**[SkinMedica](https://millionrounds.com/company/skinmedica)** Bought by [Allergan](https://millionrounds.com/fund/allergan) **Undisclosed** Nov 2012

**[Clovis Oncology](https://millionrounds.com/company/clovis-oncology)** Listed **$130M** Nov 2011

**[GenVault](https://millionrounds.com/company/genvault)** Bought by IntegenX **Undisclosed** Feb 2011

**[Zogenix](https://millionrounds.com/company/zogenix)** Listed **Undisclosed** Nov 2010

**[Immune Control](https://millionrounds.com/company/immune-control)** Bought by Corridor Pharmaceuticals **Undisclosed** Jun 2010

**[Helixis](https://millionrounds.com/company/helixis)** Bought by [Illumina](https://millionrounds.com/fund/illumina) **Undisclosed** Apr 2010

**[Alimera Sciences](https://millionrounds.com/company/alimera-sciences)** Listed **Undisclosed** Apr 2010

**[Corthera](https://millionrounds.com/company/corthera)** Bought by [Novartis](https://millionrounds.com/fund/novartis) **$620M** Dec 2009

**[BiPar Sciences](https://millionrounds.com/company/bipar-sciences)** Bought by [Sanofi Aventis](https://millionrounds.com/fund/sanofi) **$500M** Apr 2009

**[Tandem Diabetes Care](https://millionrounds.com/company/tandem-diabetes-care)** Listed **$138M** Nov 2008

**[Vascular Architects](https://millionrounds.com/company/vascular-architects)** Bought by LeMaitre Vascular **Undisclosed** Sept 2007

**[NovaCardia](https://millionrounds.com/company/novacardia)** Bought by Merck & Co. **$366M** Sept 2007

**[Orexigen Therapeutics](https://millionrounds.com/company/orexigen-therapeutics)** Listed **Undisclosed** Jul 2007

The latest 20 here. An exit counts when it came after the firm's first round in the company. From historical deal records.

New fund on file

**$164M**

raised in Dec 2016

From its SEC filing, not a journalist: a firm that has just raised has money to deploy.

## The cheque

Seed Series A Series B

Median round joined **$28M** the round, not its cheque Alone, median **$2.0M**

Led 1 of 182 rounds **1%**

- **Said size:** Up to $5.0M
- **Sole investor:** 5 rounds
- **Last cheque:** Dec 2019
- **Exits:** 24 from the portfolio

Rounds by stage said on their site

- Series B said *56*
- Series C *43*
- Series A said *32*
- Series D *19*
- Venture *17*
- Series E *7*
- Seed said *-*

Cheques by year Led Joined

2001 2019

Often in the room with

- [Versant Ventures](https://millionrounds.com/fund/versant-ventures) 25
- [Frazier Healthcare Partners](https://millionrounds.com/fund/frazier-healthcare-partners) 17
- [Montreux Growth Partners](https://millionrounds.com/fund/montreux-growth-partners) 14
- [Canaan](https://millionrounds.com/fund/canaan-partners) 13
- [New Enterprise Associates](https://millionrounds.com/fund/new-enterprise-associates) 12
- [Johnson & Johnson Development Corporation (JJDC)](https://millionrounds.com/fund/johnson-and-johnson-development-corporation) 11

**Pitching Domain Associates?** Put them on your fundraising board with this record on the card, and follow them to hear when they write a new cheque.

Add to your CRM *→*

## Who they invest alongside

The investors most often in the same rounds as Domain Associates. A count of rooms they were both in, not a relationship either has claimed.

[**Versant Ventures** VC firm **25** rounds together](https://millionrounds.com/fund/versant-ventures)[**Frazier Healthcare Partners** Private equity **17** rounds together](https://millionrounds.com/fund/frazier-healthcare-partners)[**Montreux Growth Partners** VC firm **14** rounds together](https://millionrounds.com/fund/montreux-growth-partners)[**Canaan** VC firm **13** rounds together](https://millionrounds.com/fund/canaan-partners)[**New Enterprise Associates** VC firm **12** rounds together](https://millionrounds.com/fund/new-enterprise-associates)[**Johnson & Johnson Development Corporation (JJDC)** VC firm **11** rounds together](https://millionrounds.com/fund/johnson-and-johnson-development-corporation)[**InterWest Partners** VC firm **10** rounds together](https://millionrounds.com/fund/interwest-partners)[**OrbiMed** Private equity **10** rounds together](https://millionrounds.com/fund/orbimed)[**Pappas Ventures** VC firm **10** rounds together](https://millionrounds.com/fund/pappas-ventures)[**Alta Partners** VC firm **9** rounds together](https://millionrounds.com/fund/alta-partners)[**Kleiner Perkins Caufield & Byers** VC firm **9** rounds together](https://millionrounds.com/fund/kleiner-perkins-caufield-and-byers)[**Polaris Partners** VC firm **9** rounds together](https://millionrounds.com/fund/polaris-partners)

## Recently backed

The latest companies Domain Associates put money into.

[**ChromaCode** $28M · Dec 2019](https://millionrounds.com/company/chromacode)[**Aspen Neuroscience** $6.5M · Dec 2019](https://millionrounds.com/company/aspen-neuroscience)[**Truvian Sciences** $27M · Nov 2019](https://millionrounds.com/company/truvian-sciences)[**Sera Prognostics** $36M · Nov 2019](https://millionrounds.com/company/sera-prognostics)[**Iterum Therapeutics** $65M · May 2017](https://millionrounds.com/company/iterum-therapeutics)

## Quick answers about Domain Associates

### What does Domain Associates invest in?

Domain Associates invests most often at Series B and Series C (57% of the rounds on record), in sectors such as Tech-enabled Health, Connected-health and Longevity.

### How active is Domain Associates?

182 investments on record, 0 of them in the last 12 months, and it led 1. The most recent was in Dec 2019.

### What has Domain Associates invested in recently?

Its most recent investments on record: ChromaCode (Series C, Dec 2019), Aspen Neuroscience (Seed, Dec 2019) and Truvian Sciences (Series B, Nov 2019).

### How big are Domain Associates's cheques?

The median round it joins is $28M.

### Does Domain Associates lead rounds?

Sometimes: it led 1 of its 182 investments on record (1%).

### Where does Domain Associates invest?

Most of the companies it backs are in the United States (88%) and Canada (10%).

### Is Domain Associates investing now?

No investments in the last 12 months; the latest was in Dec 2019.

### Who does Domain Associates invest alongside?

Most often Versant Ventures (25 rounds together), Frazier Healthcare Partners (17 rounds together) and Montreux Growth Partners (14 rounds together).

## Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. [How we count](https://millionrounds.com/methodology) · [Report a correction](https://millionrounds.com/corrections?slug=domain-associates) · [Is this your firm? Claim it](https://millionrounds.com/claim?org=domain-associates)